Aducanumab Virtual Symposium

FDA approves $56,000 treatment for Alzheimer’s with Questionable Efficacy – What happens Next?

Co-hosted by the Hopkins Business of Health Initiative (HBHI) and the Hopkins Economics of Alzheimer’s Disease and Services Center (HEADS Center)

Friday, July 23, 2021

This symposium is just the start of an ongoing and important conversation. We hope you continue to follow the latest on aducanumab, as well as the most important health policy current events by:

  • Following the Hopkins Business of Health Initiative on Twitter or signing up for their mailing list here.
  • Following the Hopkins Economics of Alzheimer’s Disease and Services Center on Twitter or reach out here.
  • Following Tradeoffs on Twitter, signing up for their weekly newsletter highlighting new health policy research or subscribing to the podcast.

Transcript provided HERE and Chat HERE


On June 7, 2021 the FDA approved a new treatment for Alzheimer’s, yet there remains a contentious debate about whether the drug is effective.  While this debate rages, millions of people may be eligible for this drug costing $56,000/year which, in one stroke, might double the nation’s spending on prescription drugs.  What happens next?  The Hopkins Business of Health Initiative and the Hopkins Economics of Alzheimer’s Disease and Services Center have assembled experts to lay the groundwork to inform action steps that would best leverage the opportunities and limit the challenges tied to the approval of aducanumab. 

Introductory Remarks

Dan Polsky, PhD, Bloomberg Distinguished Professor of Health Policy and Economics, Director, Hopkins Business of Health Initiative, Co-Director, Hopkins Economics of Alzheimer’s Disease and Services Center

Moderator

Dan Gorenstein, Executive Producer and Host of Tradeoffs

Panel 1 at 9:00 AM EST
Accelerated approval of Aducanumab by FDA – scientific justification and implications of approval for patients

Caleb Alexander, MD, Professor of Epidemiology, Johns Hopkins University

Marwan Noel Sabbagh, MD, FAAN, CCRI, Director of Translational Research, Cleveland Clinic Lou Ruvo Center for Brain Health

Holly Fernandez Lynch, JD, MBe John Russell Dickson, MD Presidential Assistant Professor of Medical Ethics, Assistant Professor of Law, University of Pennsylvania

Panel 2 at 10:00 AM EST
Market access to aducanumab – the clinical issues and dilemmas

Halima Amjad, MD, MPH, Assistant Professor of Medicine, Division of Geriatric Medicine and Gerontology, Johns Hopkins University School of Medicine

Michael Atkinson, Vice President MedPro Associates, Husband of Patient

Alice Bonner, Director of Strategic Partnerships for CAPABLE, Johns Hopkins University.  Former Secretary of the Executive Office of Elder Affairs for the Commonwealth of Massachusetts

Panel 3 at 11:00 AM EST
Who pays and how – consideration of options for Medicare

Tricia Neuman, Sc.D, Senior Vice President, Kaiser Family Foundation and Executive Director of Program on Medicare Policy

Sean Tunis, MD, MSc, Senior Fellow, Center for Evaluation of Value and Risk in Health, Tufts Medical Center, Mentor-in-Residence, Johns Hopkins Tech Ventures

Howard Fillit, MD, Founding Executive Director and Chief Science Officer, The Alzheimer’s Drug Discovery Foundation, Clinical Professor of Geriatric Medicine, Palliative Care and Neuroscience, The Icahn School of Medicine at Mount Sinai

Closing Remarks

Joshua Sharfstein, MD, Vice Dean for Public Health Practice and Community Engagement, Professor of the Practice, Bloomberg School of Public Health

Organizers
THE HOPKINS BUSINESS OF HEALTH INITIATIVE (HBHI) unites the Carey Business School, the Bloomberg School of Public Health, the Johns Hopkins School of Nursing, and the Johns Hopkins School of Medicine around research collaborations to improve the productivity of the nation’s health system to advance a shared vision of a healthier America, supported by an affordable and equitable, high-value healthcare.

THE HOPKINS’ ECONOMICS OF ALZHEIMER’S DISEASE AND SERVICES (HEADS) CENTER IS ONE OF THE NIH/NIA-FUNDED P30 RESEARCH CENTERS ON THE DEMOGRAPHY & ECONOMICS OF AGING AND ALZHEIMER’S DISEASE AND ALZHEIMER’S RELATED DEMENTIAS (ADRD).  THE RESEARCH THEMES OF THE HEADS CENTER ARE (1) IDENTIFYING AND QUANTIFYING THE RANGE OF ADRD CARE NEEDS AND RELATED ECONOMIC CONSEQUENCES; AND (2) EXAMINING HOW THE ORGANIZATION AND FINANCING OF SERVICES AFFECTS ACCESSIBILITY, AFFORDABILITY, QUALITY, AND EQUITY OF ADRD CARE.

TRADEOFFS IS A WEEKLY PODCAST EXPLORING THE CONFUSING, COSTLY AND OFTEN COUNTERINTUITIVE HEALTH CARE SYSTEM. COMBINING RESEARCH AND STORYTELLING EACH WEEK THEY HELP PEOPLE TO HELP FOLKS ON MAIN STREET, WALL STREET AND CAPITOL HILL HAVE SMARTER, MORE HONEST CONVERSATIONS ABOUT HEALTH POLICY. FOUNDER AND HOST, DAN GORENSTEIN, IS THE MODERATOR OF THE SYMPOSIUM.  TO LEARN ABOUT THE SHOW, INCLUDING THEIR COVERAGE OF ADUCANUMAB, SUBSCRIBE HERE

elder care resources:

elder care locator:
https://eldercare.acl.gov/Public/About/Aging_Network/AAA.aspx

national council on aging – senior centers
https://www.ncoa.org/article/get-the-facts-on-senior-centers

other options:
search for ‘senior center’ or ‘area agency on aging’ by your city or town
states may have a listing
contact your state division on aging or office of elder affairs